This segment focused on the research and development of disease-modifying therapies for neurodegenerative diseases caused by protein misfolding. Research and development activities included the discovery and preclinical development of novel small molecules and other therapeutic candidates. Technologies and methodologies employed included protein misfolding assays, high-throughput screening, and medicinal chemistry. The primary therapeutic areas were Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's disease. The goal was to improve patient outcomes by slowing or halting disease progression. Yumanity's market positioning was as a clinical-stage biopharmaceutical company with a focus on a specific unmet medical need. A key competitive advantage was the company's focus on protein misfolding as a therapeutic target. Future opportunities included expanding the pipeline and advancing clinical trials. The company had a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp.